SwanBio Therapeutics Announces FDA Investigational New Drug Clearance for First AAV-Based Gene Therapy for the Treatment of Adrenomyeloneuropathy Initiation of the Phase 1/2 Trial of SBT101 in Patients with AMN…
bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor If approved, eli-cel will be…
Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases LYON, France–(BUSINESS WIRE)– POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for…
ALD & AMN Cross-Sectional Survey: You can help! Please note: This study is not being conducted by ALD Connect. It is being conducted by Dr. Chad Heatwole from the University…
Poxel Announces its Participation at Upcoming Scientific Conferences Related to Adrenoleukodystrophy (ALD) LYON, France–(BUSINESS WIRE)– POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic…
SwanBio Therapeutics Announces New Preclinical Data Demonstrating Proof of Principle for SBT101 Gene Therapy as a Potential Treatment of Adrenomyeloneuropathy SBT101 Demonstrated Dose-Dependent Improvement of AMN Disease Markers in Mouse…
Introducing our new Peer Mentors We are excited to introduce two new Peer Mentors: Tim Mathwig and Brad Gillepsie My name is Tim Mathwig. I am 45 years old and…
Statement from the ALD Connect Board of Directors The ALD Connect Board of Directors released the following statement on August 10, 2021: We would like to acknowledge the recent press…
bluebird bio Reports Second Quarter Financial Results and Provides Operational Update – On track to complete planned business separation in 4Q 2021; each company launching with approximately 24 months of runway…
Autobahn Therapeutics Announces Orphan Drug Designation Granted to ABX-002 for the Treatment of X-linked Adrenoleukodystrophy First-of-its-kind Brain Penetrant Therapy on Track to Enter Clinical Studies in Q4 2021 SAN DIEGO –…
